Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 8/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632474 | 0.85 | FFAR1 (0.52) | FFAR1PPARAFFAR4 | |
| SCHEMBL5632476 | 0.85 | FFAR1 (0.52) | FFAR1PPARAFFAR4 | |
| SCHEMBL4472156 | 0.77 | FFAR1 (0.52) | FFAR1GRM5PTPN1PTGESPTGDR2 | |
| SCHEMBL5486388 | 0.76 | FFAR1 (0.50) | FFAR1PPARAFFAR4 | |
| SCHEMBL5634910 | 0.74 | FFAR1 (0.54) | FFAR1PPARAFFAR4 | |
| SCHEMBL30873473 | 0.74 | GRM5 (0.58) | FFAR1GRM5PTPN1PTGESPTGDR2 | |
| SCHEMBL1591331 | 0.73 | FFAR1 (0.51) | FFAR1GRM5PTPN1PTGESPTGDR2 | |
| SCHEMBL1590604 | 0.72 | PTPN1 (0.57) | FFAR1GRM5PTPN1PTGESPTGDR2 | |
| SCHEMBL8006286 | 0.71 | GRM5 (0.53) | FFAR1GRM5PTPN1PTGESPTGDR2 | |
| SCHEMBL2950490 | 0.71 | FFAR1 (0.49) | FFAR1GRM5PTPN1PTGESPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202213-B2 | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-23 | — | — | US | disclosed |
| US-6569901-B2 | (E)-(S)-2-Ethoxy-3-(4-(5-phenyl-pent-2-en-4-ynyloxy)-phenyl)-propionic acid, ethyl ester for example; treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR); diabetes, obesity | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-1254102-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20010041709-A1 | New compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041709-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | FFAR1 19/4885GRM5 615/4885PTPN1 3323/4885 |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | GLP1R, PPARG, PPARA | FFAR1 55/4885GRM5 279/4885PTPN1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.